[18F]DCFPyL PET/CT 与[18F]氟甲基胆碱 PET/CT 在前列腺癌生化复发中的比较(PYTHON):一项前瞻性、开放标签、交叉、对照研究
这项前瞻性、开放标签、随机交叉对照研究在22个欧洲中心纳入205例首次前列腺癌生化复发患者,比较[18F]DCFPyL与[18F]氟甲基胆碱PET/CT的患者水平检出率。201例完成研究,[18F]DCFPyL检出率58%(117/201)显著高于[18F]氟甲基胆碱的40%(81/201),p<0.0001。两种示踪剂均未观察到药物相关或严重不良事件。
要点
- 首次生化复发患者中,[18F]DCFPyL检出率58%(117/201)显著高于[18F]氟甲基胆碱40%(81/201),p<0.0001。
- [18F]DCFPyL对患者管理的影响为44%(90/204),[18F]氟甲基胆碱为29%(58/202)。
- 两种示踪剂均未观察到药物相关或严重不良事件。
核心结论
- 主要终点达成,证实[18F]DCFPyL在首次前列腺癌生化复发男性中检出率显著高于[18F]氟甲基胆碱,覆盖广泛PSA范围。
- [18F]DCFPyL安全且耐受良好。
研究设计与样本
- 前瞻性、开放标签、交叉、对照研究,随机分配[18F]DCFPyL(研究性药物)或[18F]氟甲基胆碱(对照)的给药顺序。
- 纳入初始治愈性治疗后PSA升高的男性,共205例,其中根治性前列腺切除术后73%(中位PSA=0.46 ng/ml [CI 0.16;27.0]),放疗后27%(中位PSA=4.23 ng/ml [CI 1.4;98.6])。
- 于2020年7月至12月在22个欧洲中心进行,两种PET/CT在最长12天间隔内完成,201例完成研究。
- 检出率定义为3名中心影像读者判读为阳性PET/CT扫描的百分比。
- 患者管理影响通过比较PET/CT前拟议治疗与考虑两种PET/CT后定义的局部治疗进行评估。
主要发现
- 患者水平检出率[18F]DCFPyL显著高于[18F]氟甲基胆碱:58%(117/201)vs 40%(81/201),p<0.0001。
- PSA≤0.5 ng/ml时,[18F]DCFPyL检出26/74(35%),[18F]氟甲基胆碱检出22/74(30%)。
- PSA 0.5至≤1.0 ng/ml时,[18F]DCFPyL检出17/31(55%),[18F]氟甲基胆碱检出10/31(32%)。
- PSA 1.01至<2.0 ng/ml时,[18F]DCFPyL检出13/19(68%),[18F]氟甲基胆碱检出6/19(32%)。
- PSA>2.0时,[18F]DCFPyL检出50/57(88%),[18F]氟甲基胆碱检出39/57(68%)。
关键数值与推荐
- 患者水平检出率:[18F]DCFPyL 58%(117/201)vs [18F]氟甲基胆碱 40%(81/201),p<0.0001。
- PSA≤0.5 ng/ml亚组检出率:[18F]DCFPyL 26/74(35%)vs [18F]氟甲基胆碱 22/74(30%)。
- PSA 0.5至≤1.0 ng/ml亚组检出率:[18F]DCFPyL 17/31(55%)vs [18F]氟甲基胆碱 10/31(32%)。
- PSA 1.01至<2.0 ng/ml亚组检出率:[18F]DCFPyL 13/19(68%)vs [18F]氟甲基胆碱 6/19(32%)。
- PSA>2.0亚组检出率:[18F]DCFPyL 50/57(88%)vs [18F]氟甲基胆碱 39/57(68%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary objective was to compare the per-patient detection rates (DR) of [18F]DCFPyL versus [18F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT), in patients with first prostate cancer (PCa) biochemical recurrence (BCR). Secondary endpoints included safety and impact on patient management (PM). METHODS: This was a prospective, open label, cross-over, comparative study with randomized treatment administration of [18F]DCFPyL (investigational medicinal product) or [18F]fluoromethylcholine (comparator). Men with rising prostate-specific antigen (PSA) after initial curative therapy were enrolled. [18F]DCFPyL and [18F]fluoromethylcholine PET/CTs were performed within a maximum time interval of 12 days. DR was defined as the percentage of positive PET/CT scans identified by 3 central imaging readers. PM was assessed by comparing the proposed pre-PET/CT treatment with the local treatment", defined after considering both PET/CTs. RESULTS: A total of 205 patients with first BCR after radical prostatectomy (73%; median PSA = 0.46 ng/ml [CI 0.16;27.0]) or radiation therapy (27%; median PSA = 4.23 ng/ml [CI 1.4;98.6]) underwent [18F]DCFPyL- and/or [18F]fluoromethylcholine -PET/CTs, between July and December 2020, at 22 European sites. 201 patients completed the study. The per-patient DR was significantly higher for [18F]DCFPyL- compared to [18F]fluoromethylcholine -PET/CTs (58% (117/201 patients) vs. 40% (81/201 patients), p < 0.0001). DR increased with higher PSA values for both tracers (PSA ≤ 0.5 ng/ml: 26/74 (35%) vs. 22/74 (30%); PSA 0.5 to ≤ 1.0 ng/ml: 17/31 (55%) vs. 10/31 (32%); PSA 1.01 to < 2.0 ng/ml: 13/19 (68%) vs. 6/19 (32%);PSA > 2.0: 50/57 (88%) vs. 39/57 (68%) for [18F]DCFPyL- and [18F]fluoromethylcholine -PET/CT, respectively). [18F]DCFPyL PET/CT had an impact on PM in 44% (90/204) of patients versus 29% (58/202) for [18F]fluoromethylcholine. Overall, no drug-related nor serious adverse events were observed. CONCLUSIONS: The primary endpoint of this study was achieved, confirming a significantly higher detection rate for [18F]DCFPyL compared to [18F]fluoromethylcholine, in men with first BCR of PCa, across a wide PSA range. [18F]DCFPyL was safe and well tolerated.
引用
- Oprea-Lager DE, Gontier E, García-Cañamaque L, et al. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging. 2023. PMID: 37341747. doi:10.1007/s00259-023-06301-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。